Flownamics

Executive Summary

Flownamics is a US-based private company specializing in automated sampling systems and bioprocess automation for the biotechnology industry. Founded in 2008, the company designs products that enable sterile, automated sampling from bioreactors, integrating with analytical instruments to improve process consistency and data integrity. Serving R&D labs, pilot plants, and production environments, Flownamics supports drug development and manufacturing by reducing contamination risk and manual intervention. The company's solutions address a critical need in bioprocessing, where real-time monitoring and automation are increasingly vital for efficiency and regulatory compliance. Despite being privately held with no disclosed funding or valuation, Flownamics holds a niche position in bioprocess automation, a market driven by the growth of biologics and personalized medicine. The company's long history since 1995 (with an official founding of 2008) suggests deep domain expertise and established customer relationships. However, limited public information on financials or recent milestones makes it challenging to assess momentum. Overall, Flownamics appears to be a stable, specialized player in a growing market, but its lack of visibility and lack of recent catalysts suggest a moderate near-term upside.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation automated sampling system70% success
• 2026Strategic partnership with major biopharma company60% success
• 2027Expansion into cell and gene therapy monitoring solutions50% success